Liquid Nanoparticles for Nanocatalytic Cancer Therapy

Adv Mater. 2023 Nov;35(48):e2306469. doi: 10.1002/adma.202306469. Epub 2023 Oct 22.

Abstract

Nanotechnology is revolutionizing cancer therapy, and catalyzes the emerging of ion-involved cancer-therapeutic modality, which unfortunately suffers from undesirable nanocarriers for efficient intracellular ion delivery. To radically extricate from this critical issue, the glutathione (GSH)-responsive organosilica network is employed to lock the liquid drops at the nanoscale via a general bottom-up strategy to achieve the systemic delivery of "ion drugs". In this work, a sulfate radical generation donor (Na2 S2 O8 ), as a paradigm "ion drug", is entrapped into this liquid nanoparticle for efficiently delivering to the tumor region. After further surface engineering with pH-responsive tannic acid-Fe2+ framework, these liquid nanoparticles achieve tumor-microenvironmental pH/GSH-dual responsive ion release (Fe2+ /Na+ /S2 O8 2- ) after reaching the tumor sites, where the Fe2+ further triggers S2 O8 2- to generate toxic •SO4 - and •OH, effectively executing cancer cell ferroptosis (Fe2+ , reactive oxygen species-ROS) and pyroptosis (Na+ , ROS). Such a tumor-responsive/specific liquid nanoplatform is highly instructive for further ion-mediated nanomedicine and disease treatment.

Keywords: liquid nanoparticles; nanocatalytic medicine; sulfate radical; tumor microenvironment.

MeSH terms

  • Cell Line, Tumor
  • Drug Delivery Systems
  • Humans
  • Nanomedicine
  • Nanoparticles* / therapeutic use
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Reactive Oxygen Species / therapeutic use
  • Tumor Microenvironment

Substances

  • Reactive Oxygen Species